Jak抑制剂时代的类风湿性关节炎单药治疗。一项多中心研究的当前患病率及相关因素。

IF 1.4 4区 医学 Q3 RHEUMATOLOGY
ARP Rheumatology Pub Date : 2023-01-01
Rodrigo Garcia-Salinas, Fernando Sommerfleck, Alfredo Vargas-Caselles, Luis Palomino-Romero, Javier Rosa, Mariana Benegas, Etel Saturansky, Pamela Giorgis, Florencia Martinez, Marcelo Abdala, Jimene Sanchez-Alcover, Emma Civit, Vanesa Espasa, Veronica Bellomio, Juan Manuel Bande, Silvia Papasidero, Veronica Saurit, Leticia Ibañez-Zurlo, Emilio Buschiazzo
{"title":"Jak抑制剂时代的类风湿性关节炎单药治疗。一项多中心研究的当前患病率及相关因素。","authors":"Rodrigo Garcia-Salinas,&nbsp;Fernando Sommerfleck,&nbsp;Alfredo Vargas-Caselles,&nbsp;Luis Palomino-Romero,&nbsp;Javier Rosa,&nbsp;Mariana Benegas,&nbsp;Etel Saturansky,&nbsp;Pamela Giorgis,&nbsp;Florencia Martinez,&nbsp;Marcelo Abdala,&nbsp;Jimene Sanchez-Alcover,&nbsp;Emma Civit,&nbsp;Vanesa Espasa,&nbsp;Veronica Bellomio,&nbsp;Juan Manuel Bande,&nbsp;Silvia Papasidero,&nbsp;Veronica Saurit,&nbsp;Leticia Ibañez-Zurlo,&nbsp;Emilio Buschiazzo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Combined therapy constitutes the standard of care in RA. Jak inhibitors (Jaki) have shown efficacy in monotherapy, a modality used in cases where it is not possible to use Disease-Modifying Anti Rheumatic Drugs (csDMARDs).</p><p><strong>Objectives: </strong>To estimate the prevalence (total and by drug), reason for using and the increase over the time of bDMARDs or tsDMARDs as monotherapy after the availability of the Jaki. To analyze the differential characteristics between patients with monotherapy vs combined therapy.</p><p><strong>Methods: </strong>Cross-sectional multicenter study. Consecutive patients with a diagnosis of RA (ACR/EULAR 2010) under treatment with bDMARDs or tsDMARDs started from 2013 were included. Socio-demographic, clinic, and therapeutic data were collected.</p><p><strong>Results: </strong>A total of 505 RA patients were included. Since 2013, the prevalence of monotherapy usage was (any) 49%. The drugs used as monotherapy were Jaki in 41% and TNF-blockers in 30%. The leading causes of monotherapy use were intolerance/adverse events (62%), medical decision or lack of adherence (37.7%). The highest socioeconomic level and a better functional status at diagnosis were predictors of monotherapy use. The use of the second line of treatments and less polypharmacy were independent factors associated with this therapeutic modality.</p><p><strong>Conclusions: </strong>The current prevalence of monotherapy in RA was 49%, the Jaki were the most used drug in this modality. Monotherapy increases from year to year. There are differential characteristics in patients using monotherapy.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"41-46"},"PeriodicalIF":1.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rheumatoid arthritis monotherapy in the Jak inhibitors Era. Current prevalence and associated factors in a multicenter study.\",\"authors\":\"Rodrigo Garcia-Salinas,&nbsp;Fernando Sommerfleck,&nbsp;Alfredo Vargas-Caselles,&nbsp;Luis Palomino-Romero,&nbsp;Javier Rosa,&nbsp;Mariana Benegas,&nbsp;Etel Saturansky,&nbsp;Pamela Giorgis,&nbsp;Florencia Martinez,&nbsp;Marcelo Abdala,&nbsp;Jimene Sanchez-Alcover,&nbsp;Emma Civit,&nbsp;Vanesa Espasa,&nbsp;Veronica Bellomio,&nbsp;Juan Manuel Bande,&nbsp;Silvia Papasidero,&nbsp;Veronica Saurit,&nbsp;Leticia Ibañez-Zurlo,&nbsp;Emilio Buschiazzo\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Combined therapy constitutes the standard of care in RA. Jak inhibitors (Jaki) have shown efficacy in monotherapy, a modality used in cases where it is not possible to use Disease-Modifying Anti Rheumatic Drugs (csDMARDs).</p><p><strong>Objectives: </strong>To estimate the prevalence (total and by drug), reason for using and the increase over the time of bDMARDs or tsDMARDs as monotherapy after the availability of the Jaki. To analyze the differential characteristics between patients with monotherapy vs combined therapy.</p><p><strong>Methods: </strong>Cross-sectional multicenter study. Consecutive patients with a diagnosis of RA (ACR/EULAR 2010) under treatment with bDMARDs or tsDMARDs started from 2013 were included. Socio-demographic, clinic, and therapeutic data were collected.</p><p><strong>Results: </strong>A total of 505 RA patients were included. Since 2013, the prevalence of monotherapy usage was (any) 49%. The drugs used as monotherapy were Jaki in 41% and TNF-blockers in 30%. The leading causes of monotherapy use were intolerance/adverse events (62%), medical decision or lack of adherence (37.7%). The highest socioeconomic level and a better functional status at diagnosis were predictors of monotherapy use. The use of the second line of treatments and less polypharmacy were independent factors associated with this therapeutic modality.</p><p><strong>Conclusions: </strong>The current prevalence of monotherapy in RA was 49%, the Jaki were the most used drug in this modality. Monotherapy increases from year to year. There are differential characteristics in patients using monotherapy.</p>\",\"PeriodicalId\":29669,\"journal\":{\"name\":\"ARP Rheumatology\",\"volume\":\"2 1\",\"pages\":\"41-46\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ARP Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ARP Rheumatology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:联合治疗是类风湿性关节炎的标准治疗。Jak抑制剂(Jaki)在单药治疗中显示出疗效,单药治疗是在不可能使用改善疾病的抗风湿药物(csDMARDs)的情况下使用的一种方式。目的:估计Jaki上市后bDMARDs或tsDMARDs单药治疗的患病率(总患病率和按药物分类)、使用原因以及随时间的增加。分析单药治疗与联合治疗的差异特点。方法:横断面多中心研究。纳入自2013年开始连续接受bDMARDs或tsDMARDs治疗的RA (ACR/EULAR 2010)患者。收集社会人口学、临床和治疗数据。结果:共纳入505例RA患者。自2013年以来,单一疗法使用率为49%。作为单一疗法使用的药物是Jaki(41%)和tnf受体阻滞剂(30%)。使用单一疗法的主要原因是不耐受/不良事件(62%),医疗决定或缺乏依从性(37.7%)。最高的社会经济水平和诊断时较好的功能状态是单药治疗使用的预测因素。二线治疗的使用和较少的多药治疗是与这种治疗方式相关的独立因素。结论:目前RA单药治疗的患病率为49%,Jaki是该模式中使用最多的药物。单药治疗逐年增加。使用单一疗法的患者有不同的特征。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Rheumatoid arthritis monotherapy in the Jak inhibitors Era. Current prevalence and associated factors in a multicenter study.

Background: Combined therapy constitutes the standard of care in RA. Jak inhibitors (Jaki) have shown efficacy in monotherapy, a modality used in cases where it is not possible to use Disease-Modifying Anti Rheumatic Drugs (csDMARDs).

Objectives: To estimate the prevalence (total and by drug), reason for using and the increase over the time of bDMARDs or tsDMARDs as monotherapy after the availability of the Jaki. To analyze the differential characteristics between patients with monotherapy vs combined therapy.

Methods: Cross-sectional multicenter study. Consecutive patients with a diagnosis of RA (ACR/EULAR 2010) under treatment with bDMARDs or tsDMARDs started from 2013 were included. Socio-demographic, clinic, and therapeutic data were collected.

Results: A total of 505 RA patients were included. Since 2013, the prevalence of monotherapy usage was (any) 49%. The drugs used as monotherapy were Jaki in 41% and TNF-blockers in 30%. The leading causes of monotherapy use were intolerance/adverse events (62%), medical decision or lack of adherence (37.7%). The highest socioeconomic level and a better functional status at diagnosis were predictors of monotherapy use. The use of the second line of treatments and less polypharmacy were independent factors associated with this therapeutic modality.

Conclusions: The current prevalence of monotherapy in RA was 49%, the Jaki were the most used drug in this modality. Monotherapy increases from year to year. There are differential characteristics in patients using monotherapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信